Share Price:

APNASPENAspen Pharmacare Hldgs2174097 (0.45%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

AGI: Covid-19 support in Mauritius

Aspen donates anaesthetic medicines to patients in critical condition An Aspen Global Incorporated Initiative Ministry of Health, Emmanuel Anquetil Building, Port Louis, 29 April 2020: In a major contribution in our fight against Covid-19, Aspen Global Incorporated, the Mauritian subsidiary of Aspen Pharmacare Holdings (a multinational pharmaceutical company), has donated approximately 30,000 vials of three… Continue reading AGI: Covid-19 support in Mauritius

Aspen responds to President Cyril Ramaphosa’s call to action on COVID-19

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced that the Group is actively focused on employees carrying out best practices in respect of the prevention and containment of COVID-19 while ensuring continued supply of medicines to patients. Stephen Saad, Aspen Group Chief Executive said, “As… Continue reading Aspen responds to President Cyril Ramaphosa’s call to action on COVID-19

Aspen increases revenue and progresses on medium-term priorities

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced unaudited interim financial results for the six months ended 31 December 2019. GROUP PERFORMANCE (CONTINUING OPERATIONS) Aspen increased revenue by 3% to R18,4 billion for the six months ended 31 December 2019. Commercial Pharma increased 2% to… Continue reading Aspen increases revenue and progresses on medium-term priorities

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.